Respiratory syncytial virus mutants, fusion peptides, particles, nucleic acids, pharmaceutical compositions, and methods of use

Abstract

Disclosed herein are compositions and methods for managing respiratory syncytial virus (RSV) infections. In certain embodiments, vaccines and pharmaceutical compositions comprise or encode an RSV G protein comprising a mutation or fusion protein arrangement disclosed herein. In certain embodiments, virus particles / virus like particles, nucleic acids, vectors, or attenuated RSV vaccines are used in methods reported herein.

Description

[0001] RESPIRATORY SYNCYTIAL VIRUS MUTANTS, FUSION PEPTIDES, PARTICLES, NUCLEIC ACIDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 525,447 filed July 7, 2023. The entirety of this application is hereby incorporated by reference for all purposes.

[0004] INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED AS AN XML FILE VIA THE OFFICE ELECTRONIC FILING SYSTEM

[0005] The Sequence Listing associated with this application is provided in XML format and is hereby incorporated by reference into the specification. The name of the XML file containing the Sequence Listing is 22148PCT.xml. The XML file is 43 KB, was created on July 2, 2024, and is being submitted electronically via the USPTO patent electronic filing system.

[0006] BACKGROUND

[0007] Human respiratory syncytial virus (RSV) causes acute lower respiratory infections. It is a major cause of hospital visits for premature babies and newborns. RSV infections also pose athreat for the elderly and immune compromised. Palivizumab is a humanized chimeric antibody that binds the RSV fusion protein (RSV F) that is clinically approved for prevention of serious lower respiratory tract disease caused by RSV in certain high-risk infants. Palivizumab has limited efficacy and sometimes causes allergic reactions. Thus, there is a need to identify additional RSV therapies.

[0008] Vaccines are often killed (inactivated) or weakened (attenuated) versions of a live viral strain. Kim et al. report that administration of a formalin-inactivated RSV vaccine was not sufficiently effective. Am J Epidemiol 89, 422-434 (1969). Attenuated RSV vaccine candidates face significant safety hurdles, and the development of pediatric RSV live-attenuated vaccine (LAV) strains that are sufficiently attenuated and immunogenic have been elusive. See Collins et al. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res, 2011,162, 80-99.

[0009] Quan et al. report virus-like particles (VLPs) consisting of an influenza virus matrix (Ml) protein core and RSV-F or -G on the surface. JID, 2011, 204:987-95. Hotard et al. report residues in the human RSV fusion protein that modulate fusion activity and pathogenesis. J Virol, 2015, 89:512-522.

[0010] Rostad et al. report a recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats. J Virol, 2016, 90(16):7508-7518.

[0011] Ha et al. report RSV platforms for G, F, or G plus F Protein VLPs. Viruses, 2020, 12(9): 906.

[0012] Brakel et al. report codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model. Virology, 2022, 575, 101-110.

[0013] See also US Patent Nos. 10,626,378 11,235,050, US2019 / 0292228, WO2014 / 152534, W02015 / 013551, and WO2017 / 075125.

[0014] References cited herein are not an admission of prior art.

[0015] SUMMARY

[0016] This disclosure relates to compositions and methods for managing respiratory syncytial virus (RSV) infections. In certain embodiments, this disclosure relates to vaccines and pharmaceutical compositions comprising an RSV G protein comprising a mutation or fusion protein arrangement disclosed herein. In certain embodiments, this disclosure relates to virus particles / virus like particles, nucleic acids, vectors, or attenuated RSV vaccines for uses reported herein. In certain embodiments, this disclosure relates to methods of vaccinating, treating, or preventing RSV infections comprising administering to a subject in need thereof an effective amount of a composition reported herein.

[0017] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, N81S, T87P, and / or R197K mutation(s).

[0018] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising the amino acid sequence of

[0019] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIV (SEQ ID NO: 27).

[0020] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNFVPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)).

[0021] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0022] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNT (SEQ ID NO: 17, Ga 1-86).

[0023] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0024] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTPP (SEQ ID NO: 18, Ga 1-86 C-terminal PP).

[0025] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0026] P SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 19, Ga 155-206).

[0027] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0028] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)).

[0029] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0030] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKP TLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)).

[0031] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of KPTLKTPRL (SEQ ID NO: 21, linker Gb). In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0032] QRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTCW AICKRIPNKKPGKKTTTKPTK KPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 20, Ga 150-210 plus Gb 150-210).

[0033] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0034] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICS NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206).

[0035] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of KPTTKQRQNK (SEQ ID NO: 28, Ga 145-154).

[0036] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of CWAIAC (SEQ ID NO: 22, Ga CX4C).

[0037] In certain embodiments, the recombinant RSV G protein comprises the S177R and / or S177Q mutation.

[0038] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0039] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or

[0040] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q).

[0041] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0042] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQ (SEQ ID NO: 34, Ga 1-96).

[0043] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQLGISPSNPSE (SEQ ID NO: 35, Ga 1- 106).

[0044] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0045] QRQNKPP SKPNNDFHFEVFNFVPC SIC SNNPTCW AICKRIPNKKPGKKTTTKPTK KPTLK (SEQ ID NO: 36, Ga 150-210).

[0046] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0047] TPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 37, Gb 150-210).

[0048] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0049] QRQNKPP SKPNNDFHFEVFNFVPC SIC SNNPTCW AICKRIPNKKPGKKTTTKPTK KPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 20, Ga 150-210 plus Gb 150-210).

[0050] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0051] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210),

[0052] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210),

[0053] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQLGISPSNPSEQRQNKPPSKPNNDF HFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-106 plus Ga 150-210 plus Gb 150-210), or

[0054] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210).

[0055] In certain embodiments, this disclosure relates to virus particles / virus like particles comprising any of the recombinant RSV G protein as reported herein.

[0056] In certain embodiments, this disclosure relates to nucleic acids encoding the recombinant RSV protein, such as G protein and / or F protein as reported herein in operable combination with a heterologous promoter.

[0057] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0058] In certain embodiments, this disclosure relates to attenuated RSV strains comprising an RSV G protein and / or RSV F protein as reported herein.

[0059] In certain embodiments, this disclosure relates to vectors comprising a nucleic acid as reported herein or encoding the recombinant RSV G protein as reported herein.

[0060] In certain embodiments, this disclosure relates to methods of vaccinating against or treating for an RSV infection comprising administering an effective amount of a vaccine or pharmaceutical composition comprising RSV G protein, viral particle / virus like particle, nucleic acid, attenuated RSV strain, or vector as reported herein to a subject in need thereof.

[0061] In certain embodiments, this disclosure relates to vaccine or pharmaceutical composition comprising RSV G protein, viral particle / virus like particle, nucleic acid, attenuated RSV stain, attenuated RSV virus, or vector as reported herein to a subject in need thereof.

[0062] In certain embodiments, this disclosure contemplates the use of RSV G proteins disclosed herein in combination with RSV F proteins with prefusion stabilizing construction / mutations.

[0063] In certain embodiments, the vaccine or pharmaceutical composition is administered intranasally or intramuscularly. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0064] Figure 1 illustrates a sequence alignment using BLASTP (NCBI) of Ga 1-86 plus 155-206 (Ga) (SEQ ID NO: 1) Query (Q) and Ga CX4C 1-86 plus 145-206) (SEQ ID NO: 9) Subject (S). A difference is that Ga CX4C has an additional 10 amino acid peptide linker KPTTKQRQNK (SEQ ID NO: 28, Ga 145-154) and a variant sequence between the two cystines, CWAIAC (SEQ ID NO: 22, Ga CX4C).

[0065] Figure 2 illustrates a sequence alignment using BLASTP (NCBI) of Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T-Ga / Ga) (SEQ ID NO: 3) Query (Q) and group A 1-86 plus 150-210 (deleted Ga amino acids 87 to 149), plus group B 150-210 tandem Ga plus Gb (T-Ga / Gb) (SEQ ID NO: 5) Subject (S). Difference are that T-Ga / Gb has an additional 5 amino acid peptide linker QRQNK (SEQ ID NO: 23), additional 10 amino acid peptide linker KPTLKTPRL (SEQ ID NO: 21, linker Gb), a variant sequence NPPKKPKDDY (SEQ ID NO: 24) and a C-terminal segment GNNQLCKSICKT (SEQ ID NO: 25) within having a sequence between the two cystines, CKSIC (SEQ ID NO: 26).

[0066] Figure 3 shows data on antibody responses in mice to RSV F plus G protein VLPs with / without G Peptide Tandem Repeats. The bars indicate antibody response (absorbance) by Enzyme immunoassay (EIA) for the F (F IgG), subgroup A G (Ga IgG) or subgroup B G (Gb IgG) proteins. Immunogens are control VLPs (Ctl), pre-fusion stabilized F protein (F only), F plus Ga (aa 155-206. Galx), F plus tandem repeat of Ga (Ga2x), and F plus Ga and Gb (aa 155-206) in tandem.

[0067] Figure 4 shows data indicating expression of functional prefusion F and G on VLPs proteins (VLPs, prefusion F alone, prefusion F with Ga+b protein as 3 different constructs: 1-86, 1-96, and 1-106). Expression of functional proteins were determined using Western Blot and ELISA assays (3D3 is anti-G antibody, Motavizumab is anti-F antibody recognizing both prefusion and post-fusion, and D25 is an antibody which only binds to prefusion F).

[0068] Figure 5 shows data indicating immunization with Ga, Gb, and F with Alum adjuvant and a squalene oil-in-water emulsions adjuvant AdaS03 (containing squalene and DL-a-tocopherol, and a surfactant, polysorbate 80 (Tween® 80) which is a sugar substituted with an unsaturated long chain fatty acid and polyethylene glycol polymer having an average of about 80 ethylene glycol units total). AddaS03 induces more potent antibody production and elicited higher serum titers than Alum. Figure 6 shows data using neutralizing assays indicating a higher titer to A2 virus.

[0069] Figure 7 shows data indicating reduction of lung viral load in vaccinated mice - qPCR measurements of homogenize lung tissue was used to probe for RSV genes. There were significant differences between the control VLPs group and groups immunized with prefusion and G 1-86 or G i-96. G 1-106 elicited neutralizing abs with an elevation of virus.

[0070] DETAILED DISCUSSION

[0071] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0072] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.

[0073] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.

[0074] An "embodiment" of this disclosure refers to an example, but not necessarily limited to such example. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

[0075] Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. In this specification and in the claims that follow reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.

[0076] As used in this disclosure and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") have the meaning ascribed to them in U.S. Patent law in that they are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0077] "Consisting essentially of' or "consists of' or the like, when applied to methods and compositions encompassed by the present disclosure refers to compositions like those disclosed herein that exclude certain prior art elements to provide an inventive feature of a claim, but which may contain additional composition components or method steps, etc., that do not materially affect the basic and novel characteristic(s) of the compositions or methods.

[0078] A ’’nucleic acid” refers to and DNA- or RNA-molecule and is used synonymous with polynucleotide. Wherever herein reference is made to a nucleic acid or nucleic acid sequence encoding a particular protein and / or peptide, said nucleic acid or nucleic acid sequence, respectively, preferably also comprises regulatory sequences allowing in a suitable host, e.g., a human being, its expression, i.e., transcription and / or translation of the nucleic acid sequence encoding the particular protein or peptide.

[0079] "Amino acid sequence" is defined as a sequence composed of any one of the 20 naturally appearing amino acids, amino acids which have been chemically modified, or composed of synthetic amino acids. The terms "protein" and "peptide" refer to compounds comprising amino acids joined via peptide bonds and are used interchangeably. As used herein, where "amino acid sequence" is recited herein to refer to an amino acid sequence of a protein molecule. An "amino acid sequence" can be deduced from the nucleic acid sequence encoding the protein. Furthermore, unless the context demands otherwise, the term "peptide" and "polypeptide" and "protein" are used interchangeably to refer to amino acids in which the amino acid residues are linked by covalent peptide bonds or alternatively (where post-translational processing has removed an internal segment) by covalent disulfide bonds, etc. The ammo acid chains can be of any length and comprise at least two amino acids or at least three amino acids, they can include domains of proteins or full-length proteins. Unless otherwise stated the terms peptide, polypeptide, and protein also encompass various modified forms thereof, including but not limited to glycosylated forms, phosphorylated forms, etc.

[0080] The term “comprising” in reference to a peptide having an amino acid sequence refers a peptide that may contain additional N-terminal (amine end) or C-terminal (carboxylic acid end) amino acids, i.e., the term is intended to include the amino acid sequence within a larger peptide. The term “consisting of’ in reference to a peptide having an amino acid sequence refers a peptide having the exact number of amino acids in the sequence and not more or having not more than a range of amino acids expressly specified in the claim. In certain embodiments, the disclosure contemplates that the “N-terminus of a peptide consists of an amino acid sequence,” which refers to the N-terminus of the peptide having the exact number of amino acids in the sequence and not more or having not more than a range of amino acids specified in the claim; however, the C- terminus may be connected to additional amino acids, e.g., as part of a larger peptide. Similarly, the disclosure contemplates that the “C-terminus of a peptide consists of an amino acid sequence,” which refers to the C-terminus of the peptide having the exact number of amino acids in the sequence and not more or having not more than a range of amino acids specified in the claim; however, the N-terminus may be connected to additional amino acids, e.g., as part of a larger peptide.

[0081] The term "recombinant" when made in reference to a nucleic acid molecule refers to a nucleic acid molecule that is comprised of segments of nucleic acid joined together by means of molecular biological techniques. The term "recombinant" when made in reference to a protein or a polypeptide refers to a protein molecule that is expressed using a recombinant nucleic acid molecule.

[0082] As used herein, a “heterologous” gene, nucleic acid, promoter, antigen, protein, etc., is understood to be referring to a nucleic acid or amino acid sequence which is not present in naturally occurring nucleic acids or proteins.

[0083] The terms "vector" or " expression vector " refer to a recombinant nucleic acid containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism or expression system, e.g., cellular or cell-free. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.

[0084] Protein "expression systems" refer to in vivo (e.g., host cell) and in vitro (cell free) systems. Systems for recombinant protein expression typically utilize somatic cells transfecting with a DNA or mRNA expression vector that contains the template. The cells are cultured under conditions such that they translate the desired protein. Expressed proteins are extracted for subsequent purification. In vivo protein expression systems using prokaryotic and eukaryotic cells are well known. Proteins may be recovered using denaturants and protein-refolding procedures. In vitro (cell-free) protein expression systems typically use translation-compatible extracts of whole cells or compositions that contain components sufficient for transcription, translation, and optionally post-translational modifications such as RNA polymerase, regulatory protein factors, transcription factors, ribosomes, tRNA cofactors, amino acids, and nucleotides. In the presence of an expression vectors, these extracts and components can synthesize proteins of interest. Cell-free systems typically do not contain proteases and enable labeling of the protein with modified amino acids. Some cell free systems incorporated encoded components for translation into the expression vector. See, e.g., Shimizu et al., Cell-free translation reconstituted with purified components, 2001, Nat. Biotechnol, 19, 751-755 and Asahara & Chong, Nucleic Acids Research, 2010, 38(13): el41, both hereby incorporated by reference in their entirety.

[0085] A “selectable marker” is a nucleic acid introduced into a recombinant vector that encodes a polypeptide that confers a trait suitable for artificial selection or identification (report gene), e.g., beta-lactamase confers antibiotic resistance, which allows an organism expressing beta-lactamase to survive in the presence antibiotic in a growth medium. Another example is thymidine kinase, which makes the host sensitive to ganciclovir selection. It may be a screenable marker that allows one to distinguish between wanted and unwanted cells based on the presence or absence of an expected color. For example, the lac-z-gene produces a beta-galactosidase enzyme which confers a blue color in the presence of X-gal (5-bromo-4-chloro-3-indolyl-P-D-galactoside). If recombinant insertion inactivates the lac-z-gene, then the resulting colonies are colorless. There may be one or more selectable markers, e.g., an enzyme that can complement to the inability of an expression organism to synthesize a particular compound required for its growth (auxotrophic) and one able to convert a compound to another that is toxic for growth. URA3, an orotidine-51 phosphate decarboxylase, is necessary for uracil biosynthesis and can complement ura3 mutants that are auxotrophic for uracil. URA3 also converts 5-fluoroorotic acid into the toxic compound 5 -fluorouracil. Additional contemplated selectable markers include any genes that impart antibacterial resistance or express a fluorescent protein. Examples include, but are not limited to, the following genes: ampr, camr, tetr, blasticidinr, neor, hygr, abxr, neomycin phosphotransferase type II gene (nptll), p-glucuronidase (gus), green fluorescent protein (gfp), egfp, yfp, mCherry, p- galactosidase (lacZ), lacZa, lacZAM15, chloramphenicol acetyltransferase (cat), alkaline phosphatase (phoA), bacterial luciferase (luxAB), bialaphos resistance gene (bar), phosphomannose isomerase (pmi), xylose isomerase (xylA), arabitol dehydrogenase (atlD), UDP- glucose:galactose-l-phosphate uridyltransferasel (galT), feedback-insensitive a subunit of anthranilate synthase (0ASA1D), 2-deoxy glucose (2-DOGR), benzyladenine-N-3 -glucuronide, E. coli threonine deaminase, glutamate 1 -semialdehyde aminotransferase (GSA-AT), D-amino acidoxidase (DAAO), salt-tolerance gene (rstB), ferredoxin-like protein (pflp), trehalose-6-P synthase gene (AtTPSl), lysine racemase (lyr), dihydrodipicolinate synthase (dapA), tryptophan synthase beta 1 (AtTSBl), dehalogenase (dhlA), mannose-6-phosphate reductase gene (M6PR), hygromycin phosphotransferase (HPT), and D-serine ammonialyase (dsdA).

[0086] A "label" refers to a detectable compound or composition that is conjugated directly or indirectly to another molecule, such as an antibody or a protein, to facilitate detection of that molecule. Specific, non-limiting examples of labels include fluorescent tags, enzymatic linkages, and radioactive isotopes. A label includes the incorporation of a radiolabeled amino acid or the covalent attachment of biotinyl moieties to a polypeptide that can be detected by marked avidin (for example, streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionucleotides (such as 35S or 1311) fluorescent labels (such as fluorescein isothiocyanate (FITC), rhodamine, lanthanide phosphors), enzymatic labels (such as horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (such as a leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), or magnetic agents, such as gadolinium chelates. In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

[0087] In certain embodiments, the disclosure relates to recombinant polypeptides comprising sequences disclosed herein or variants or fusions thereof wherein the amino terminal end or the carbon terminal end of the amino acid sequence are optionally attached to a heterologous amino acid sequence, label, or reporter molecule.

[0088] In certain embodiments, the disclosure relates to the recombinant vectors comprising a nucleic acid encoding a polypeptide disclosed herein or chimeric protein thereof.

[0089] In certain embodiments, the recombinant vector optionally comprises a mammalian, human, insect, viral, bacterial, bacterial plasmid, yeast associated origin of replication or gene such as a gene or retroviral gene or lentiviral LTR, TAR, RRE, PE, SLIP, CRS, and INS nucleotide segment or gene selected from tat, rev, nef, vif, vpr, vpu, and vpx or structural genes selected from gag, pol, and env.

[0090] In certain embodiments, the recombinant vector optionally comprises a gene vector element (nucleic acid) such as a selectable marker region, lac operon, a CMV promoter, a hybrid chicken B-actin / CMV enhancer (CAG) promoter, tac promoter, T7 RNA polymerase promoter, SP6 RNA polymerase promoter, SV40 promoter, internal ribosome entry site (IRES) sequence, cis-acting woodchuck post regulatory element (WPRE), scaffold-attachment region (SAR), inverted terminal repeats (ITR), FLAG tag coding region, c-myc tag coding region, metal affinity tag coding region, streptavidin binding peptide tag coding region, polyHis tag coding region, HA tag coding region, MBP tag coding region, GST tag coding region, polyadenylation coding region, SV40 polyadenylation signal, SV40 origin of replication, Col El origin of replication, fl origin, pBR322 origin, or pUC origin, TEV protease recognition site, loxP site, Cre recombinase coding region, or a multiple cloning site such as having 5, 6, or 7 or more restriction sites within a continuous segment of less than 50 or 60 nucleotides or having 3 or 4 or more restriction sites with a continuous segment of less than 20 or 30 nucleotides.

[0091] "Variant" refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide and retains essential properties. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall (homologous) and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions, and / or deletions). A substituted or inserted ammo acid residue may or may not be one encoded by the genetic code. A variant of a polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.

[0092] Modifications and changes can be made in the structure of the peptides of this disclosure and still result in a molecule having similar characteristics as the peptide (e.g., a conservative amino acid substitution). For example, certain amino acids can be substituted for other amino acids in a sequence without appreciable loss of activity. Because it is the interactive capacity and nature of a peptide that defines the biological functional activity of the peptide, certain ammo acid sequence substitutions can be made in a peptide sequence and nevertheless obtain a peptide with like properties. Amino acid substitutions are generally based on the relative similarity of the ammo acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take one or more of the foregoing characteristics into consideration are well known to those of skill in the art and include, but are not limited to (original residue: exemplary substitution): (Ala to Gly or Ser), (Arg to Lys), (Asn to Gin or His), (Asp to Glu, Cys, or Ser), (Gin to Asn), (Glu to Asp), (Gly to Ala), (His to Asn, Gin), (Leu to He or Vai), (Lys to Arg), (Met to Leu, Tyr), (Ser to Thr), (Thr to Ser), (Trp to Tyr), (Tyr to Trp or Phe), and (Vai to He or Leu). Embodiments of this disclosure thus contemplate functional or biological equivalents of a peptide as set forth above. In certain embodiments, peptide variants are those having greater than 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 97%, and 99% sequence identity to the peptide of interest. In general, homologous peptides of the present disclosure are characterized as having one or more amino acid substitutions, deletions, and / or additions.

[0093] "Identity," as known in the art, is a relationship between two or more peptide sequences, as determined by comparing the sequences. In the art, "identity" also refers to the degree of sequence relatedness between peptides as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods. Preferred methods to determine identity are designed to give the largest match between the sequences tested. In certain embodiments, sequence "identity" refers to the number of exactly matching amino acids (expressed as a percentage) in a sequence alignment between two sequences of the alignment calculated using the number of identical positions divided by the greater of the shortest sequence or the number of equivalent positions excluding overhangs wherein internal gaps are counted as an equivalent position.

[0094] Methods to determine identity and similarity are codified in publicly available computer programs. The percent identity between two sequences can be determined by using analysis software (Sequence Analysis Software Package of the Genetics Computer Group, Madison, Wis) that incorporates the Needelman & Wunsch (J Mol Biol, 48 443-453, 1970) algorithm (e.g. NBLAST and XBLAST). The US National Institutes of Health has a website that provides for aligning two protein sequences using BLASTP, which was used to create certain sequence alignments disclosed herein. The default parameters may be used to determine the identity for the peptides of the present disclosure.

[0095] "Subject" refers to any animal, preferably a human patient, livestock, or domestic pet.

[0096] As used herein, the terms "treat" and "treating" are not limited to the case where the subject (e g., patient) is cured and the disease is eradicated. Rather, embodiments, of the present disclosure also contemplate treatment that merely reduces symptoms, and / or delays disease progression.

[0097] As used herein, the terms "prevent" and "preventing" include the prevention of the recurrence, spread or onset. It is not intended that the present disclosure be limited to complete prevention. In some embodiments, the onset is delayed, or the severity of the disease is reduced.

[0098] The term "virus particles "as used herein refers to virus-like particles, virosomes, or particles created and / or isolated by a replicating virus, e.g., chimeric virus, attenuated virus.

[0099] The term "virus-like particle" (VLPs) as used herein refers to a membrane-surrounded viral core structure having viral envelope proteins. Further, viral core proteins are located within the membrane of the VLP. Typically, a virus-like particle does not carry genetic information encoding for the proteins of the virus-like particle. In general, virus-like particles lack the viral genome and, therefore, are noninfectious. Also, virus-like particles can often be produced in large quantities by heterologous expression and can be purified. Some virus-like particles may contain a nucleic acid distinct from their genome. Typically, a virus-like particle is non replicative and noninfectious lacking all or part of the viral genome, in particular the replicative and infectious components of the viral genome. The term "virosome" as used herein refers to a virus particle that is similar to a virus-like particle, except that a virosome does not contain a viral core protein.

[0100] The terms “chimeric respiratory syncytial virus” or “chimeric RSV” refer to a nucleic acid that contains sufficient RSV genes to allow the genome or antigenome to replicate in host cells (e g., Vero cells) and the nucleic acid sequence is altered to include at least one nucleic acid segment that is not structurally the same a natural RSV strain, i.e., such that the nucleotide sequence of the RSV strain does not occur naturally over the whole RSV genome. A chimeric respiratory syncytial virus includes an RSV gene wherein the codons are altered to be different from those naturally occurring gene even though the RSV produces a polypeptide with an identical amino acid sequence to those naturally expressed. Different strains of RSV will have different nucleotide sequences and express proteins with different amino acid sequences that have similar functions. Thus, a chimeric RSV includes an RSV gene wherein one or more genes from one strain are replaced from genes in alternative or second strain such that the nucleic acid sequence of the entire RSV genome is not identical to an RSV found in nature. In certain embodiments, the chimeric RSV includes those strains where nucleic acids are deleted after a codon for starting translation in order to truncate the proteins expression, provided such truncation pattern for the genome is not found in naturally occurring RSV. In certain embodiments, the chimeric RSV includes those which are infectious but cannot replicate in a human subject. In certain embodiments, the chimeric RSV includes those which are infectious and can replicate in a human subject.

[0101] The term "fusion" when used in reference to a polypeptide refers to the expression product of two or more coding sequences obtained from different sources such that they do not exist together in a natural environment, that have been cloned together and that, after translation, act as a single polypeptide sequence. Fusion polypeptides are also referred to as "hybrid" polypeptides. The coding sequences include those obtained from the same or from different species of organisms.

[0102] The RSV fusion protein (F) is a surface glycoprotein used to fuse to target cell membranes. The RSV fusion protein exists in a pre-fusion conformation. The F protein is an RSV immunogen. Anti-RSV neutralizing antibodies are often directed against the F protein in the pre-fusion conformation. Mutations for stabilizing the prefusion F protein include S155C and S290C for disulfide formation (DS), S190F and V207L for cavity filling (Cavl), and D486H, E487Q, F488W, and D489H to form stable RSV F trimers (TriC). See McLellan et al. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus, Science. 2013, 342(6158): 592-598. As used herein, an “RSV G” protein, or like terms refers to an attachment RSV glycoprotein G and all known variants or substantial fragments thereof. One example has the amino acid sequence

[0103] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAMIISTSLIIV AIIFIASANHKITSTTTIIQDATNQIKNTTPTYLTQNPQLGISPSNPSDITSLITTILDSTTPGV KSTLQSTTVGTKNTTTTQAQPNKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKRTTTKPTKKPTPKTTKKGPKPQTTKSKEAPTTKPTEEPTINTTKTNII TTLLTSNTTRNPELTSQMETFHSTSSEGNPSPSQVSITSEYPSQPSSPPNTPR (SEQ ID NO: 15, UniProtKB / Swiss-Protein Accession number P27022.1) which is an RSV G protein sequence wherein the N-terminal Methionine (M) is position one. Other examples include those designated by Accession numbers P03423.1, CAA51765.1, AAD02944.1, CAA83874.1, AAD02941.1, CAA83870.1 , P27021.1, AEO45938.1, CAA51761.1, CAA83871.1, AAU43727.1 , AEO45918.1, AEO45888.1, AEO45878.1, AEO45849.1, AEC32086.1, AEQ98767.1, AEQ63333.1,

[0104] CAA83875.1, AEO45908.1, AEO45948.1, AEO45898.1, AEO45928.1, AAC36327.1,

[0105] ACO83296.1, AEO45829.1, AEQ66845.1, ACI03570.1, AEO45868.1, P20895.2, AAD02943.1, AAX23993.1, AEQ66853.1, AEO45839.1, AEJ87998.1, and AEJ88006.1.

[0106] Throughout the present patent specification, when reference is made to specific amino acid residues or specific amino acid regions, e.g., in the RSV F and G proteins, by referring to their amino residue number or numbers and unless otherwise stated, the numbering is based on the RSV amino acid sequences provided herein in the sequence listing and in the Figures. It should be noted, and one of skill in the art will understand, that different RSV sequences may have different numbering systems, for example, if there are additional amino acid residues added or removed as compared to SEQ ID NO: 15. As such, it isto beunderstood that when specific amino acid residues are referred to by their number, the description is not limited to only amino acids located at precisely that numbered position when counting from the beginning of a given amino acid sequence, but rather that the equivalent / corresponding amino acid residue in any and all RSV G sequences is intended — even if that residue is not at the same precise numbered position, for example if the RSV sequence is shorter or longer than SEQ ID NO: 15, or has insertions or deletions as compared to SEQ ID NO. 15. One of skill in the art can readily determine what is the corresponding / equivalent amino acid position to any of the specific numbered residues recited herein, for example by aligning a given RSV G sequence to SEQ ID NO: 15 or to any of the other RSV G amino acid sequences provided herein.

[0107] UniProtKB / Swiss-Prot: P03420.1 (SEQ ID NO: 16) provides for an RSV F protein sequence wherein the N-terminal Methionine (M) is position one:

[0108] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPPTNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTN KAVVSL SNGVS VLT SK VLDLKNYIDKQLLPIVNKQ SC SISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEINLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCY GKTKCTASNKNRGIIKTFSNGCDYVSNKGMDTVSVGNTLYYVNKQEGKSLYVKGEPIIN FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLS LIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 16).

[0109] Prefusion RSV F protein variant DS-Cavl (pF)) has the following amino acid sequence

[0110] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIELSNIKKNKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7).

[0111] This disclosure relates to compositions and methods for managing respiratory syncytial virus (RSV) infections. In certain embodiments, this disclosure relates to vaccines and pharmaceutical compositions comprising an RSV G protein comprising mutations reported herein and / or fusion protein arrangements and F and / or prefusion F constructs / mutations. In certain embodiments, this disclosure relates to virus particles / virus like particles, nucleic acids, vectors, or attenuated RSV vaccines for uses reported herein. In certain embodiments, this disclosure relates to methods of vaccinating, treating, or preventing RSV infections comprising administering to a subject in need thereof an effective amount of a composition reported herein.

[0112] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, N81S, T87P, and / or R197K mutation(s).

[0113] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, and I49V mutations.

[0114] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, N81S, T87P, and R197K mutations.

[0115] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, and R197K mutations.

[0116] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, and T87P mutations.

[0117] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, and N81S, mutations.

[0118] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, and I49Vmutations.

[0119] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, and M48I, mutations.

[0120] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, T87P, and R197K mutations.

[0121] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, N81S, and R197K mutations.

[0122] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, I49V, and R197K mutations.

[0123] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, and R197K mutations.

[0124] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, N81S, and T87P, mutations.

[0125] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, I49V, and T87P, mutations. In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, and T87P mutations.

[0126] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, and R197K mutations.

[0127] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, and T87P, mutations.

[0128] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, and N81S, mutations.

[0129] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, T87P, and R197K mutations.

[0130] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, N81S, and R197K mutations.

[0131] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, I49V, and R197K mutations.

[0132] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, and R197K mutations.

[0133] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, N81S, and T87P, mutations.

[0134] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, I49V, and T87P, mutations.

[0135] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, and T87P mutations.

[0136] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, and R197K mutations.

[0137] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, and T87P mutations.

[0138] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, and N81S mutations.

[0139] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, N81S, and R197K mutations. In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, T87P, and R197K mutations.

[0140] In certain embodiments, this disclosure relates to recombinant RSV G proteins comprising R15K, G29C, M48I, I49V, N81S, and T87P mutations.

[0141] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0142] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFE VFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNFVPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variants thereof.

[0143] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0144] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNT (SEQ ID NO: 17, Ga 1-86) or variants thereof.

[0145] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0146] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTPP (SEQ ID NO: 18, Ga 1-86 C-terminal PP) or variants thereof.

[0147] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of PSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 19, Ga 155-206 (Ga)) or variants thereof.

[0148] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0149] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFE VFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variants thereof.

[0150] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)) or variants thereof.

[0151] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of KPTLKTPRL (SEQ ID NO: 21, linker Gb) or variants thereof.

[0152] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0153] QRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTCWAICKRIPNKKPGKKTTTKPTK KPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 20, Ga 150-210 plus Gb 150-210) or variants thereof.

[0154] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0155] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFEVFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0156] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of KPTTKQRQNK (SEQ ID NO: 28, Ga 145-154) or variants thereof.

[0157] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of CWAIAC (SEQ ID NO: 22, Ga CX4C) or variants thereof.

[0158] In certain embodiments, the recombinant RSV G protein comprises the S177R and / or S177Q mutation.

[0159] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0160] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIAAIIFIAS ANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQNNPTC WAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0161] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0162] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQ (SEQ ID NO: 34, Ga 1-96) or variants thereof.

[0163] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0164] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQLGISPSNPSE (SEQ ID NO: 35, Ga 1- 106) or variants thereof.

[0165] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0166] QRQNKPP SKPNNDFHFEVFNFVPC SIC SNNPTCW AICKRIPNKKPGKKTTTKPTK KPTLK (SEQ ID NO: 36, Ga 150-210) or variants thereof.

[0167] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0168] TPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 37, Gb 150-210) or variants thereof.

[0169] QRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTCW AICKRIPNKKPGKKTTTKPTK KPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 20, Ga 150-210 plus Gb 150-210) or variants thereof.

[0170] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0171] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKP TLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof. In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0172] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0173] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0174] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQLGISPSNPSEQRQNKPPSKPNNDF HFEVFNFVPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-106 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0175] In certain embodiments, the recombinant RSV G protein comprises the amino acid sequence of

[0176] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0177] In certain embodiments, this disclosure relates to virus particles / virus like particles comprising any of the recombinant RSV G protein as reported herein.

[0178] In certain embodiments, this disclosure relates to nucleic acids encoding the recombinant RSV protein, such as G protein and / or F protein as reported herein in operable combination with a heterologous promoter.

[0179] In certain embodiments, the nucleic acid is RNA, mRNA, or DNA.

[0180] In certain embodiments, this disclosure relates to live attenuated RSV strains comprising an RSV G protein and / or RSV F protein as reported herein. In certain embodiments, this disclosure relates to vectors comprising a nucleic acid as reported herein or encoding the recombinant RSV G protein as reported herein.

[0181] In certain embodiments, this disclosure relates to vaccine or pharmaceutical composition or vaccine comprising RSV G protein, viral particle / virus like particle, nucleic acid, attenuated RSV stain, attenuated RSV virus, or vector as reported herein to a subject in need thereof.

[0182] In certain embodiments, this disclosure relates to G constructs with prefusion stabilized F (Fpre). In certain embodiments, it is contemplated that the unmutated versions of the G constructs decrease the immunogenicity of Fpre and one or more of these mutations maintain and / or improve the immunogenicity of Fpre. In certain embodiments, it is contemplated that the G constructs reported herein improve the Fpre vaccines facilitating clinical use in young children, elderly, or other immune compromised patients.

[0183] RSV Ga Tandem and prefusion F Peptides

[0184] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0185] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTPPSKPNNDFHFEVFNFVPCSICSNNPTCW AICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0186] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0187] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC W AICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0188] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0189] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0190] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTPPSKPNNDFHFEVFNFVPCSICSNNPTCW AICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0191] In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0192] In certain embodiments, the recombinant vector is an adenoviral vector or modified vaccinia virus Ankara (MV A).

[0193] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0194] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCCCTCCAAGCAAGCCCAACAA

[0195] CGACTTCCACTTCGAGGTGTTCAACTTCGTGCCCTGCAGCATCTGCAGCAACAATCC TACCTGCTGGGCCATCTGCAAGAGAATCCCCAACAAGAAGCCCGGCAAAAAGACCA CCACAAAGCCCACAAAGAAGCCC (SEQ ID NO: 2, Ga).

[0196] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0197] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0198] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0199] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof and the RSV F peptide has the amino acid sequence of

[0200] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIELSNIKKNKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variant thereof.

[0201] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0202] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0203] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0204] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof and the RSV F peptide has the amino acid sequence of

[0205] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variant thereof.

[0206] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0207] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0208] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0209] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof and the RSV F peptide has the amino acid sequence of

[0210] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQ SNRVFCDTMNSLTLP SEVNLCNVDIFNPKYDCKIMT SKTD VS S S VIT SLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variant thereof.

[0211] In certain embodiments, this disclosure relates to a recombinant vector comprising an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0212] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof.

[0213] In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0214] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)) or variant thereof and the RSV F peptide has the amino acid sequence of

[0215] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variant thereof.

[0216] In certain embodiments, this disclosure relates to a recombinant vector which is an adenoviral vector or recombinant modified vaccinia virus Ankara (MV A).

[0217] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0218] ATGGAACTGCTGATCCTGAAGGCCAACGCCATCACCACCATCCTGACCGCTG TGACCTTCTGCTTCGCCAGCGGCCAGAACATCACCGAGGAATTCTACCAGAGCACCT GTAGCGCCGTGTCCAAGGGCTACCTGAGCGCCCTGCGGACCGGCTGGTACACCAGC GTGATCACCATCGAGCTGAGCAACATCAAGAAAAACAAGTGCAACGGCACCGACGC CAAGATCAAGCTGATCAAGCAGGAACTGGACAAGTACAAGAACGCCGTGACCGAG CTGCAGCTGCTGATGCAGAGCACCCCCGCCACCAACAACCGGGCTAGACGCGAGCT GCCTCGGTTCATGAACTACACCCTGAACAACGCCAAAAAGACCAACGTGACCCTGA GCAAGAAGCGGAAGCGGCGGTTCCTGGGCTTCCTGCTGGGCGTGGGCAGCGCCATT GCTAGCGGAGTGGCCGTGTGCAAGGTGCTGCACCTGGAAGGCGAAGTGAACAAGAT CAAGTCCGCCCTGCTGAGCACCAACAAGGCCGTGGTGTCCCTGAGCAACGGCGTGT CCGTGCTGACCTTCAAGGTGCTGGATCTGAAGAACTACATCGACAAGCAGCTGCTGC CCATCCTGAACAAGCAGAGCTGCAGCATCAGCAACATCGAGACAGTGATCGAGTTC CAGCAGAAGAACAACCGGCTGCTGGAAATCACCCGCGAGTTCAGCGTGAACGCCGG CGTGACCACCCCCGTGTCCACCTACATGCTGACCAACAGCGAGCTGCTGAGCCTGAT CAACGACATGCCCATCACCAACGACCAGAAAAAGCTGATGAGCAACAACGTGCAGA TCGTGCGGCAGCAGAGCTACTCCATCATGTGCATCATCAAAGAAGAGGTGCTGGCCT ACGTGGTGCAGCTGCCCCTGTACGGCGTGATCGACACCCCCTGCTGGAAGCTGCACA CCAGCCCCCTGTGCACCACCAACACCAAAGAGGGCAGCAACATCTGCCTGACCCGG ACCGACCGGGGCTGGTACTGCGATAATGCCGGCAGCGTGTCATTCTTTCCACAAGCC GAGACATGCAAGGTGCAGAGCAACCGGGTGTTCTGCGACACCATGAACAGCCTGAC CCTGCCCTCCGAAGTGAACCTGTGCAACGTGGACATCTTCAACCCTAAGTACGACTG CAAGATCATGACCTCCAAGACCGACGTGTCCAGCTCCGTGATCACCTCCCTGGGCGC CATCGTGTCCTGCTACGGCAAGACCAAGTGCACCGCCAGCAACAAGAACCGGGGCA TCATCAAGACCTTCAGCAACGGCTGCGACTACGTGTCCAACAAGGGGGTGGACACC GTGTCCGTGGGCAACACCCTGTACTACGTGAACAAACAGGAAGGCAAGAGCCTGTA CGTGAAGGGCGAGCCCATCATCAACTTCTACGACCCCCTGGTGTTCCCCAGCGACGA GTTCGACGCCAGCATCAGCCAGGTCAACGAGAAGATCAACCAGAGCCTGGCCTTCA TCAGAAAGAGCGACGAGCTGCTGCACAATGTGAATGCCGTGAAGTCCACCACCAAT ATCATGATCACCACAATCATCATCGTGATCATCGTCATCCTGCTGTCCCTGATCGCC GTGGGCCTGCTGCTGTACTGCAAGGCCCGGTCCACCCCTGTGACCCTGTCCAAGGAC CAGCTGAGCGGCATCAACAATATCGCCTTCTCCAACTGA (SEQ ID NO: 8, pF).

[0219] RSV T-Ga / Ga

[0220] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0221] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFI AS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC W AICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof.

[0222] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0223] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof.

[0224] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0225] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0226] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof.

[0227] In certain embodiments, the recombinant vector is a live attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0228] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof.

[0229] In certain embodiments, the recombinant vector is an adenoviral vector or recombinant modified vaccinia virus Ankara (MV A).

[0230] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0231] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCCCTCCAAGCAAGCCCAACAA CGACTTCCACTTCGAGGTGTTCAACTTCGTGCCCTGCAGCATCTGCAGCAACAATCC TACCTGCTGGGCCATCTGCAAGAGAATCCCCAACAAGAAGCCCGGCAAAAAGACCA CCACAAAGCCCACAAAGAAGCCCCCTCCAAGCAAGCCCAACAACGACTTCCACTTC GAGGTGTTCAACTTCGTGCCCTGCAGCATCTGCAGCAACAATCCTACCTGCTGGGCC ATCTGCAAGAGAATCCCCAACAAGAAGCCCGGCAAAAAGACCACCACAAAGCCCA CAAAGAAGCCC (SEQ ID NO: 4, (T-Ga / Ga).

[0232] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0233] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFI AS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC W AICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof.

[0234] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0235] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof and the RSV F peptide has the amino acid sequence of

[0236] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variant thereof.

[0237] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0238] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFI AS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof.

[0239] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0240] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variant thereof and the RSV F peptide has the amino acid sequence of

[0241] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variant thereof.

[0242] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0243] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0244] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)).

[0245] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNFVPC SIC SNNPTC W AICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variants thereof and the RSV F peptide has the amino acid sequence of

[0246] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0247] In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0248] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNF VPC SIC SNNPTC W AICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variants thereof.

[0249] In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0250] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKPPPSKPNNDFHFEVFNFVPCSICSNNPTCW AICKRIPNKKPGKK TTTKPTKKP (SEQ ID NO: 3, Ga 1-86 plus 155-206 plus 155-206, tandem Ga plus Ga (T- Ga / Ga)) or variants thereof and the RSV F peptide has the amino acid sequence of MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN K A VVSL SNGVS VLTFK VLDLKNYIDKQLLPILNKQ SC SI SNIET VIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0251] RSV T-Ga / Gb

[0252] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0253] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)) or variant thereof.

[0254] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0255] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)) or variant thereof.

[0256] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0257] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)) or variants thereof.

[0258] In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0259] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)) or variants thereof.

[0260] In certain embodiments, the recombinant vector is an adenoviral vector recombinant or modified vaccinia virus Ankara (MVA).

[0261] In certain embodiments, the attenuated RSV strain, recombinant vector, or nucleic acid comprise the nucleic acid sequence of

[0262] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCCAGAGACAGAACAAGCCTCC AAGCAAGCCCAACAACGACTTCCACTTCGAGGTGTTCAACTTCGTGCCCTGCAGCAT CTGCAGCAACAATCCTACCTGCTGGGCCATCTGCAAGAGAATCCCCAACAAGAAGC CCGGCAAAAAGACCACCACAAAGCCCACAAAGAAGCCCACACTGAAAACCCCTCG GCTGAAGAACCCTCCTAAGAAGCCCAAGGACGACTACCACTTCGAGGTGTTCAACT TCGTGCCCTGCAGCATCTGCGGCAACAACCAGCTGTGCAAGAGCATCTGCAAGACA ATCCCCAGCAACAAGCCAAAGAAGAAGCCTACCATCAAGCCCACAAACAAACCCAC CACCAAGACC (SEQ ID NO: 6, (T-Ga / Gb)).

[0263] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0264] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0265] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0266] In certain embodiments, the nucleic acid which is mRNA, RNA, or DNA.

[0267] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0268] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0269] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0270] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0271] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0272] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCCAGAGACAGAACAAGCCTCC AAGCAAGCCCAACAACGACTTCCACTTCGAGGTGTTCAACTTCGTGCCCTGCAGCAT CTGCAGCAACAATCCTACCTGCTGGGCCATCTGCAAGAGAATCCCCAACAAGAAGC CCGGCAAAAAGACCACCACAAAGCCCACAAAGAAGCCCACACTGAAAACCCCTCG GCTGAAGAACCCTCCTAAGAAGCCCAAGGACGACTACCACTTCGAGGTGTTCAACT

[0273] TCGTGCCCTGCAGCATCTGCGGCAACAACCAGCTGTGCAAGAGCATCTGCAAGACA ATCCCCAGCAACAAGCCAAAGAAGAAGCCTACCATCAAGCCCACAAACAAACCCAC CACCAAGACC (SEQ ID NO: 31, Ga / Ga / Gb).

[0274] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0275] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0276] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0277] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0278] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0279] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0280] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0281] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0282] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0283] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIELSNIKKNKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0284] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA. In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0285] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0286] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0287] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof, and the RSV F peptide has the amino acid sequence of

[0288] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0289] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0290] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1 -86 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0291] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0292] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, Ga 1-86 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0293] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQ SNRVFCDTMNSLTLP SEVNLCNVDIFNPKYDCKIMT SKTD VS S S VIT SLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0294] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0295] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0296] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0297] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP CSICSNNPTCWAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFV PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0298] In certain embodiments, the nucleic acid which is mRNA, RNA, or DNA.

[0299] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0300] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP CSICSNNPTCWAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFV PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0301] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0302] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFEVFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0303] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0304] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCACACCTACCTACCTGACACA GAACCCTCAGCTGGGCATCAGCCCTAGCAATCCTAGCGAGCAGAGACAGAACAAGC CTCCAAGCAAGCCCAACAACGACTTCCACTTCGAGGTGTTCAACTTCGTGCCCTGCA GCATCTGCAGCAACAATCCTACCTGCTGGGCCATCTGCAAGAGAATCCCCAACAAG AAGCCCGGCAAAAAGACCACCACAAAGCCCACAAAGAAGCCCACACTGAAAACCC CTCGGCTGAAGAACCCTCCTAAGAAGCCCAAGGACGACTACCACTTCGAGGTGTTC AACTTCGTGCCCTGCAGCATCTGCGGCAACAACCAGCTGTGCAAGAGCATCTGCAA GACAATCCCCAGCAACAAGCCAAAGAAGAAGCCTACCATCAAGCCCACAAACAAA CCCACCACCAAGACC (SEQ ID NO: 32).

[0305] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0306] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0307] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0308] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0309] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0310] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0311] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0312] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0313] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0314] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0315] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0316] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFV PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0317] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0318] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof, and the RSV F peptide has the amino acid sequence of

[0319] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0320] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0321] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0322] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQQRQNKPPSKPNNDFHFEVFNFVP C SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF V PCSICGNNQLCKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 29, Ga 1-96 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0323] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0324] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0325] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQD AT SQIKNTQRQNKPPSKPNNDFHFE VFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNF VPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDD YHFE VFNF VPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0326] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0327] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNF VPCSICGNNQL CK SICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0328] In certain embodiments, the nucleic acid which is mRNA, RNA, or DNA.

[0329] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0330] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0331] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0332] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0333] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0334] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCCAGAGACAGAACAAGCCTCC AAGCAAGCCCAACAACGACTTCCACTTCGAGGTGTTCAACTTCGTGCCCTGCAGCAT CTGCAGCAACAATCCTACCTGCTGGGCCATCTGCAAGAGAATCCCCAACAAGAAGC CCGGCAAAAAGACCACCACAAAGCCCACAAAGAAGCCCACACTGAAAACCCCTCG GCTGAAGAACCCTCCTAAGAAGCCCAAGGACGACTACCACTTCGAGGTGTTCAACT TCGTGCCCTGCAGCATCTGCGGCAACAACCAGCTGTGCAAGAGCATCTGCAAGACA ATCCCCAGCAACAAGCCAAAGAAGAAGCCTACCATCAAGCCCACAAACAAACCCAC CACCAAGACCCAGAGACAGAACAAGCCTCCAAGCAAGCCCAACAACGACTTCCACT TCGAGGTGTTCAACTTCGTGCCCTGCAGCATCTGCAGCAACAATCCTACCTGCTGGG CCATCTGCAAGAGAATCCCCAACAAGAAGCCCGGCAAAAAGACCACCACAAAGCCC ACAAAGAAGCCCACACTGAAAACCCCTCGGCTGAAGAACCCTCCTAAGAAGCCCAA GGACGACTACCACTTCGAGGTGTTCAACTTCGTGCCCTGCAGCATCTGCGGCAACAA CCAGCTGTGCAAGAGCATCTGCAAGACAATCCCCAGCAACAAGCCAAAGAAGAAGC CTACCATCAAGCCCACAAACAAACCCACCACCAAGACC (SEQ ID NO: 33, Ga / Gb / Ga / Gb).

[0335] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0336] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0337] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0338] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0339] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0340] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0341] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0342] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0343] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0344] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0345] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0346] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0347] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0348] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0349] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTQRQNKPPSKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRZPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof, and the RSV F peptide has the amino acid sequence of

[0350] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0351] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0352] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIP SNKPKKKPTIKPTNKPTTKTQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof.

[0353] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0354] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 30, Ga 1-86 plus Ga 150-210 plus Gb 150-210 plus Ga 150-210 plus Gb 150-210) or variants thereof and the RSV F peptide has the amino acid sequence of

[0355] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0356] RSV Ga CX4C

[0357] In certain embodiments, this disclosure relates to a peptide virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0358] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFEVFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0359] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0360] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICS NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0361] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0362] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFE VFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0363] In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0364] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFEVFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0365] In certain embodiments, the recombinant vector is an adenoviral vector or recombinant modified vaccinia virus Ankara (MV A).

[0366] In certain embodiments, the attenuated RSV strain, recombinant vector, or nucleic acid comprises the nucleic acid sequence of

[0367] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCAAGCCTACCACCAAGCAGAG ACAGAACAAGCCTCCAAGCAAGCCCAACAACGACTTCCACTTCGAGGTGTTCAACT TCGTGCCCTGCAGCATCTGCAGCAACAATCCTACCTGCTGGGCCATCGCCTGCAAGA GAATCCCCAACAAGAAGCCCGGCAAAAAGACCACCACAAAGCCCACAAAGAAGCC C (SEQ ID NO: 10, Ga CX4C).

[0368] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFEVFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variant thereof.

[0369] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFE VFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof and the RSV F peptide has the amino acid sequence of

[0370] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDK YKNA VTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0371] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0372] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFEVFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0373] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0374] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICS NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof and the RSV F peptide has the amino acid sequence of

[0375] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNA VTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN K A VVSL SNGVS VLTFK VLDLKNYIDKQLLPILNKQ SC SI SNIET VIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0376] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0377] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0378] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICS NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0379] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0380] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICS NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof and the RSV F peptide has the amino acid sequence of

[0381] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQ SNRVFCDTMNSLTLP SEVNLCNVDIFNPKYDCKIMT SKTD VS S S VIT SLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof. In certain embodiments, the recombinant vector is an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0382] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICS NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof.

[0383] In certain embodiments, the attenuated RSV strain encodes an RSV F peptide and G fusion peptide having the amino acid sequence

[0384] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTKPTTKQRQNKPP SKPNNDFHFE VFNF VPC SIC S NNPTCWAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206) or variants thereof and the RSV F peptide has the amino acid sequence of

[0385] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0386] RSV Ga 145 S177R

[0387] In certain embodiments, this disclosure relates to peptide, a virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0388] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof. In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0389] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof.

[0390] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0391] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0392] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof.

[0393] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0394] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof.

[0395] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0396] ATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGAAAGAACCTGG GACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCTGAACCTGAAG TCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCACCAGCCTGATC ATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCCTACCACAGCC ATCATCCAGGACGCCACAAGCCAGATCAAGAACACCAAGCCTACCACCAAGCAGAG ACAGAACAAGCCTCCAAGCAAGCCCAACAACGACTTCCACTTCGAGGTGTTCAACT TCGTGCCCTGCAGCATCTGCAGAAACAATCCTACCTGCTGGGCCATCTGCAAGAGAA TCCCCAACAAGAAGCCCGGCAAAAAGACCACCACAAAGCCCACAAAGAAGCCC (SEQ ID NO: 12, Ga S177R). In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0397] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variant thereof.

[0398] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0399] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof and the RSV F peptide has the amino acid sequence of

[0400] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0401] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0402] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof.

[0403] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) pr variants thereof and the RSV F peptide has the amino acid sequence of

[0404] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNA VTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0405] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0406] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0407] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof.

[0408] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0409] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof and the RSV F peptide has the amino acid sequence of

[0410] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNA VTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0411] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0412] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof.

[0413] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0414] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) or variants thereof and the RSV F peptide has the amino acid sequence of

[0415] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQ SNRVFCDTMNSLTLP SEVNLCNVDIFNPKYDCKIMT SKTD VS S S VIT SLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof. RSV Ga 145 S177Q

[0416] In certain embodiments, this disclosure relates to a peptide, virus-like particle (VLP) or vaccine particle comprising an RSV G fusion peptide having the amino acid sequence

[0417] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0418] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV G fusion peptide having the amino acid sequence

[0419] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0420] In certain embodiments, the nucleic acid which is mRNA, RNA, or DNA.

[0421] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV G fusion peptide having the amino acid sequence

[0422] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0423] In certain embodiments, this disclosure relates to a live attenuated RSV strain encoding an RSV G fusion peptide having the amino acid sequence

[0424] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0425] In certain embodiments, this disclosure relates to an attenuated RSV strain, recombinant vector, or nucleic acid comprising the nucleic acid sequence of

[0426] ATCCGCCACCATGAGCAAGAACAAGGACCAGCGGACCGCCAAGACACTGGA AAGAACCTGGGACACCCTGAACCATCTGCTGTTCATCAGCAGCTGCCTGTACAAGCT GAACCTGAAGTCTGTGGCCCAGATCACCCTGAGCATCCTGGCCATCGTGATCAGCAC CAGCCTGATCATTGCCGCCATCATCTTTATCGCCAGCGCCAACCACAAAGTGACCCC TACCACAGCCATCATCCAGGACGCCACAAGCCAGATCAAGAACACCAAGCCTACCA CCAAGCAGAGACAGAACAAGCCTCCAAGCAAGCCCAACAACGACTTCCACTTCGAG GTGTTCAACTTCGTGCCCTGCAGCATCTGCCAGAACAATCCTACCTGCTGGGCCATC TGCAAGAGAATCCCCAACAAGAAGCCCGGCAAAAAGACCACCACAAAGCCCACAA AGAAGCCC (SEQ ID NO: 14, Ga S177Q).

[0427] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0428] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0429] In certain embodiments, this disclosure relates to a virus-like particle (VLP) or vaccine particle comprising an RSV F peptide and G fusion peptide having the amino acid sequence

[0430] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof and the RSV F peptide has the amino acid sequence of

[0431] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN K A VVSL SNGVS VLTFK VLDLKNYIDKQLLPILNKQ SC SI SNIET VIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof. In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0432] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0433] In certain embodiments, this disclosure relates to a nucleic acid encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0434] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof and the RSV F peptide has the amino acid sequence of

[0435] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0436] In certain embodiments, the nucleic acid is mRNA, RNA, or DNA.

[0437] In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0438] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof. In certain embodiments, this disclosure relates to a recombinant vector encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0439] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof, and the RSV F peptide has the amino acid sequence of

[0440] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0441] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0442] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof.

[0443] In certain embodiments, this disclosure relates to an attenuated RSV strain encoding an RSV F peptide and G fusion peptide having the amino acid sequence

[0444] MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q) or variants thereof and the RSV F peptide has the amino acid sequence of

[0445] MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSV ITIEL SNIKKNKCNGTD AKIKLIKQELDKYKNAVTELQLLMQ STP ATNNRARRELPRFMN YTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTN KAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREF SVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVL AYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAE TCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSC YGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPII NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTTNIMITTIIIVIIVILL SLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN (SEQ ID NO: 7, Prefusion F DS-Cavl (pF)) or variants thereof.

[0446] Vaccination methods

[0447] In certain embodiments, this disclosure relates to methods of vaccinating against or treating for an RSV infection comprising administering an effective amount of a vaccine or pharmaceutical composition comprising RSV G protein, viral particle / virus like particle, nucleic acid, attenuated RSV strain, or vector as reported herein to a subject in need thereof.

[0448] In certain embodiments, this disclosure relates to methods of vaccinating against or treating for an RSV infection comprising administering an effective amount of a vaccine or pharmaceutical composition comprising RSV G protein, viral particle / virus like particle, nucleic acid, attenuated RSV strain, or vector as reported herein to a subject in need thereof.

[0449] In certain embodiments, the subject is a premature baby, newborn, infant, elderly, or immune compromised.

[0450] In certain embodiments, the subject is a human subject is 2, 12, or 16 years old or older. In certain embodiments, the subject is a human subject is 2, 12, or 15 years old or less than 2, 12, or 16 years old. In certain embodiments, the subject is a human subject is 55 or 65 years old or older. In certain embodiments, the subject is a human subject is an infant, e.g., from one month to two years of age. In certain embodiments, the subject is a human subject is a child, e.g., from one two to twelve years of age. In certain embodiments, the subject is a human subject is an adolescent, e.g., from twelve to sixteen years of age. In certain embodiments, the subject is a human subject sixteen years of age or older.

[0451] In certain embodiments, the subject is immune compromised due to the need to maintain an immune suppressive drug(s) therapy, e.g., the subject is or diagnoses with DiGeorge syndrome, Wiskott-Aldrich syndrome, Bruton’s agammaglobulinemia, the subject is receiving (being administered) chemotherapy or radiation due to being diagnosed with cancer, the subject is receiving corticosteroids due to a diagnosis of rheumatoid arthritis, lupus, vasculitis, or the subject is a solid organ recipient to prevent rejection of the transplanted organ.

[0452] Pharmaceutical Compositions

[0453] In certain embodiments, this disclosure relates to vaccine or pharmaceutical composition or vaccine comprising RSV G protein, viral particle / virus like particle, nucleic acid, attenuated RSV stain, attenuated RSV virus, or vector as reported herein to a subject in need thereof The pharmaceutical compositions provided herein may generally include one or more pharmaceutically acceptable and / or approved carriers, additives, antibiotics, preservatives, adjuvants, diluents and / or stabilizers. Such auxiliary substances can be water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, or the like. Suitable carriers are typically large, slowly metabolized molecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates, or the like.

[0454] A vaccine is typically understood to be a prophylactic or therapeutic material providing at least one antigen or antigenic function. Typically, the vaccine comprises a conventional saline or buffered aqueous solution medium in which the composition suspended or dissolved. Upon introduction into a host, the vaccine provokes an immune response including, but not limited to, the production of antibodies and / or cytokines and / or the activation of cytotoxic T cells, antigen presenting cells, helper T cells, dendritic cells and / or other cellular responses.

[0455] In certain embodiments, the vaccine optionally includes an adjuvant, i.e., a non-specific stimulator of the immune response or substances that allow generation of a depot in the host which when combined with the vaccine provides for an even more enhanced immune response. Examples include incomplete Freund's adjuvant and aluminum hydroxide.

[0456] In certain embodiments, the vaccine is a nucleic acid, recombinant vector, or attenuated vaccine, e.g., DNA, RNA, or mRNA-based vaccine which encodes a peptide antigen(s) disclosed herein having at least one open reading frame that can be translated by a cell or an organism provided with the nucleic acid, DNA, RNA, or mRNA. If more than one protein is translated, the proteins can be expressed in one vector / nucleic acid or in multiple (a plurality of) separate nucleic acids / vectors. The product of translation is a peptide or protein disclosed herein or viral particle containing such a protein or proteins, that may act as an antigen, preferably as an immunogen. The product may also be a fusion protein composed of more than one immunogen, e.g., a fusion protein that has two or more peptides or proteins derived from the same or different virus-proteins, wherein the peptides or proteins are optionally linked by self-cleaving linker sequences.

[0457] In certain embodiments, nucleic acid, DNA, RNA, or mRNA may be designed to have two (bicistronic) or more (multicistronic) open reading frames (ORF). An open reading frame in this context is a sequence including a start codon that can be used as a location to start translation of the encoded nucleic acid into a peptide or protein. Translation of such nucleic acid(s) yields two (bicistronic) or more (multicistronic) distinct translation products / proteins (provided the ORFs are not identical). For expression in eukaryotes such nucleic acids may comprise an internal ribosomal entry site (IRES) sequence which allows for expression of two or more proteins on a single nucleic acid molecule.

[0458] In certain embodiments, the peptides, virus particles, virus-like particles, nucleic acid, recombinant vector, or attenuated vaccine, may be administered naked without being associated with any further vehicle.

[0459] In certain embodiments, the peptides, virus particles, virus-like particles, nucleic acids, recombinant vectors, or attenuated vaccines may be administered in a pharmaceutical composition having a pharmaceutically acceptable excipient selected from lactose, sucrose, mannitol, triethyl citrate, dextrose, cellulose, methyl cellulose, ethyl cellulose, hydroxyl propyl cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, croscarmellose sodium, polyvinyl N- pyrrolidone, crospovidone, ethyl cellulose, povidone, methyl and ethyl acrylate copolymer, polyethylene glycol, fatty acid esters of sorbitol, lauryl sulfate, gelatin, glycerin, glyceryl monooleate, silicon dioxide, titanium dioxide, talc, corn starch, carnauba wax, stearic acid, sorbic acid, magnesium stearate, calcium stearate, castor oil, mineral oil, calcium phosphate, starch, carboxymethyl ether of starch, iron oxide, triacetin, acacia gum, esters, or salts thereof.

[0460] In certain embodiments, the pharmaceutical composition is in the form of a sterilized pH buffered aqueous salt solution or a saline phosphate buffer between a pH of 6 to 8, optionally comprising a saccharide or polysaccharide.

[0461] In certain embodiment, the pharmaceutically acceptable excipient is a cationic or polycationic compound and / or with a polymeric carrier. In certain embodiments, the peptides, virus particles, virus-like particles, nucleic acids, recombinant vectors, or attenuated RSV are in a pharmaceutical composition associated with or complexed with a cationic or polycationic compound or a polymeric carrier and optionally an adjuvant. In certain embodiments, the cationic or polycationic compound is protamine, spermine, spermidine, poly-L-lysine (PLL), polyhistidine, or poly-arginine, cationic polysaccharides, such as chitosan, polybrene, cationic polymers, polyethyleneimine (PEI), homo- and co-polymers of lactic acid and glycolic acid, or polymethylmethacrylate.

[0462] In certain embodiments, the peptides, virus particles, virus-like particles, nucleic acids, recombinant vectors, or attenuated RSV may be contained in a pharmaceutical composition with or administered in combination with an adjuvant. Contemplated adjuvants suitable for depot and delivery are cationic or polycationic compounds, liposomes, chitosan, alum solution, aluminium hydroxide, aluminium salts aluminium phosphate gel, aluminium hydroxide gel (alum), polyphosphazene, squalene, squalene water emulsion, CpG oligonucleotides (nucleic acids with unmethylated CpG motifs), 1 -alpha, 25-dihydroxy -vitamin D3, calcium phosphate gel, dimethyl dioctadecyl ammonium bromide, dehydroepiandrosterone, dimyristoylphosphatidylcholine, myristoyl phosphatidylglycerol, deoxycholic acid sodium salt, imiquimod, interferon gamma, interleukin-1 beta, interleukin-2, interleukin-7, interleukin- 12, 7-allyl-8-oxoguanosine, acetylmuramyl-alanyl-isoglutamine, N-acetyl muramyl-L-threonyl-D-isoglutamine, NAc-Mur-L- Ala-D-Gln-OCHs, QS-21, Quil-A (Quil-A saponin), sorbitan trioleate, 2,6,10,15,19,23- hexamethyltetracosan, stearyl tyrosine, lipid A, 4 '-monophosphoryl lipid A, 3-O-desacyl-4'- monophosphoryl lipid A (MPL™), liposomes containing lipid A, lipid A adsorbed on aluminium hydroxide.

[0463] Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, albumin, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, citric acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, hydrophilic polymers such as polyvinyl pyrrolidone, cellulose based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, gelatin, polyethylene polyoxypropylene block polymers, polyethylene glycol and antioxidants including ascorbic acid and methionine; preservatives; low molecular weight (less than about 10 residues) polypeptides; proteins; and amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine. Tn advantageous embodiments, the excipient may be one or more selected from the list consisting of NaCl, trehalose, sucrose, mannitol, or glycine.

[0464] The disclosure also encompasses products obtainable by further processing of a liquid formulation, such as a frozen, lyophilized or spray-dried product. Upon reconstitution, these solid products can become liquid formulations as described herein (but are not limited thereto). In its broadest sense, therefore, the term "formulation" encompasses both liquid and solid formulations. However, solid formulations are understood as derivable from the liquid formulations (e.g., by freezing, freeze-drying or spray-drying), and hence have various characteristics that are defined by the features specified for liquid formulations herein.

[0465] In certain embodiments, the formulations are isotonic in relation to human blood. Isotonic solutions possess the same osmotic pressure as blood plasma, and so can be intravenously infused into a subject without changing the osmotic pressure of the blood plasma.

[0466] In certain embodiments, it is contemplated that attenuated RSV, recombinant vectors, and nucleic acids, virus particle, and peptides may be stored as a unit dosage form with a titer formulated in about 10 mM Tris, 140 mM NaCl pH 7.7. For the preparation of vaccine shots, e.g., 102- 108or 102- 109virus particles or virus like particles, can be lyophilized in phosphate-buffered saline (PBS) in the presence of peptone and human albumin in a sealed container, preferably a glass ampoule. Alternatively, the vaccine shots can be produced by stepwise freeze-drying a formulation. This formulation can contain additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other aids such as antioxidants or inert gas, stabilizers, or recombinant proteins (e.g., human serum albumin) suitable for in vivo administration. For vaccination or therapy, the lyophilisate can be dissolved in an aqueous solution, preferably physiological saline, or tris(hydroxymethyl)aminomethane buffer. In certain embodiments, the vaccine or pharmaceutical composition is administered intranasally or intramuscularly.

[0467] In certain embodiments, the vaccine or pharmaceutical composition is administered either systemically or locally, i.e., parenteral, subcutaneous, intravenous, intramuscular, intranasal, or any other path of administration. The mode of administration, the dose and the number of administrations can be optimized.

[0468] In certain embodiments, this disclosure relates to kits containing materials useful for the vaccination, treatment, or prevention of an RSV infection as described above is provided. In certain embodiments, the kit comprises a container, a product label and a package insert. Suitable containers include, for example, bottles, vials, syringes, and boxes containing the same. The containers may be of a variety of materials, e.g., glass, plastic, or cardboard. The container holds the composition which is effective in treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a peptide, virus particle / virus like particle, nucleic acid, vector, or attenuated virus as disclosed herein. The product label on, or associated with, the container indicates that the composition is used for treating the condition of choice. In certain embodiments, the kit may further comprise a second container comprising a pharmaceutically acceptable buffer, such as a phosphate buffer saline or a citrate buffered saline. It may further include other materials desirable from a user or commercial standpoint, including other buffers, diluents, fdters, needles, and syringes. In certain embodiments, a dosage unit form can be, e.g., in the format of a prefdled syringe, an ampoule, cartridge or a vial.

[0469] In certain embodiments, this disclosure relates to kits or articles of manufacture, comprising a polypeptide, virus particle, nucleic acid, vector, or attenuated virus formulation thereof as disclosed herein and instructions for use by, e.g., a healthcare professional. The kits or articles of manufacture may include a container, vial, or a syringe containing the formulation as described herein.

[0470] Preferably, the container, vial, or syringe is composed of glass, plastic, or a polymeric material chosen from a cyclic olefin polymer or copolymer. The syringe, ampoule, cartridge, or vial can be manufactured of any suitable material, such as glass or plastic and may include rubber materials, such as rubber stoppers for vials and rubber plungers and rubber seals for syringes and cartridges. In certain embodiments, the kit may further comprise instructions for use and / or a clinical package leaflet. In any embodiment of the products as defined herein, this disclosure also encompasses the presence of packaging material, instructions for use, and / or clinical package leaflets, e.g., as required by regulatory aspects.

[0471] RSV Platforms for G, F, or G plus F Proteins VLPs

[0472] Contemplated are RSV VLP platforms, M plus P and M plus M2-1 that had F and G, F and a G peptide, or a truncated F and G on their surface. Immunoblots of sucrose gradient purified particles showed co-expression of M, G, and F with both VLP platforms. Electron microscopy imaging and immunogold labeling confirmed VLP-like structures with surface exposed projections consistent with F and G proteins. In mice, the VLPs induced both anti-F and -G protein antibodies and, on challenge, reduced lung viral titer and inflammation indicating that these RSV VLP platforms provide a tool to study the structure of F and G and their interactions and flexible platforms to develop VLP vaccines in which all components contribute to RSV-specific immune responses. See Ha et al., Viruses 2020, 12, 906, 1-17.

[0473] RSV is a single-stranded, negative sense RNA virus. The RSV genome (approximately 15.2 kb) includes 10 genes that encode for 11 proteins. Glycoproteins, fusion (F), attachment (G), and small hydrophobic (SH), are expressed on the virion envelope. The F and G proteins induce effective neutralizing antibodies and protective immunity. Most neutralizing antibodies in human serum are against the pre-fusion form of F. The G protein typically elicits less potent neutralizing antibodies. Structurally, the G protein consists of a conserved region that contains a CX3C chemokine motif that enables its binding to the CX3C chemokine receptor, CX3CR1. Experiments performed in in the BALB / c mouse indicate that G induces disease causing inflammatory responses that can be blocked by inhibiting G binding to CX3CR1 with passive administration of an anti-G monoclonal antibody, G peptide vaccine-induced antibodies, or by mutating the CX3C motif. G binding to CX3CR1 mediates infection of primary human airway epithelial cells. F and G interactions are suggested by co-immunoprecipitation experiments cryo-electron tomography (cryo-ET) studies of G’s effect on F in virions, and the need for both a mutated F and G to induce lung mucus in mice.

[0474] Reported herein are RSV VLPs that incorporated F and / or with the RSV M and P or M and M2-1. Contemplated are VLPs with M and M2-1, in addition to VLPs with M and P. RSV VLPs with surface expression of F and G, F and a G peptide, and F without most of its extracellular domain and G were generated and demonstrated the ability to protect RSV challenged mice.

[0475] Cells, Media, and Plasmids:

[0476] Cells (293F) were stably transfected with plasmid pcDNA6 / TR and cultured in Freestyle™ 293 media on a shaker at 37°C, 8% CO2. DNA plasmids (pcDNA3.1) containing codon-optimized RSV genes M, M2-1, P, G, and F from A2 strain were used. The plasmids were digested by Kpnl and XhOI enzymes and cloned into Kpnl and XhOI double digested pcDNA4 / TO or pcDNA5 / TO vector. See Ha et al. Viruses. 2020, 12(9): 906 Human codon optimized truncated G consisting of amino acids 1-86 plus 155-206 was synthesized. The gene provided in pUC57 plasmid was digested by BamHI and XhOI restriction enzymes and cloned into BamHI and XhOI digested pcDNA5 / TO vector. All genes were sequence confirmed prior to transfection. To generate VLPs, 293F cells were sequentially and stably transfected with the RSV genes i.e., 293F cells were stably transfected with genes expressing M, M2-1, and pF and then different the versions of Ga and / or Gb.

[0477] Virus-like particles expression and purification: A total of 20-30 * 106293F cells were induced with 2 pg / mL of doxycycline for 72 h. Cells were centrifuged at 300* g for 10 min and the VLP-containing media was filtered through 0.45 pm filter followed by centrifugation through 20% sucrose cushion at 12,200* g for 2 h at 4 °C. The top layer of cell media and sucrose was thoroughly removed, and the pellet was soaked in sterile PBS for 1 h on ice and resuspended. For sucrose gradient experiments, preparation of a linear sucrose gradient was used, 1 mb of the gradient was removed before the resuspended VLPs were layered onto the gradient and centrifuged at 11,000 * g for 12 h at 4 °C. Ten 1-mL fractions were removed from top, diluted 3 * with sterile PBS, and centrifuged at 12,000 * g for 1 h at 4 °C on a bench-top centrifuge. Supernatants were removed, and pellets were soaked in sterile PBS for 1 h on ice before being resuspended.

[0478] F, Ga, and Gb ELISA:

[0479] The secreted form of F, Ga, or Gb protein antigens were produced from stably-transfected 293F cells in serum-free media and coated onto a 96-well microtiter plate in coating buffer (15 mMNa2CO3, 35 mMNaHCCh, 3 mMNaNs, pH 9.4-9.6). The plates were incubated in 2% nonfat dry milk dissolved in PBS blocking solution for 2 h at 37 °C, washed with PBS-T (PBS plus 0.15% Tween-20), and serum specimens at 1 :200 dilution added to the wells, incubated for 1 h at 37 °C, the plates washed with PBS-T, and goat anti mouse IgG-HRP (1:5000) added and incubated for 1 h at 37 °C. Color was developed with o-Phenylenediamine dihydrochloride (OPD) substrate and the reaction stopped after 30 min at RT with 4N H2SO4. The absorbance was measured at an optical density (OD) of 490 nm using a microplate reader and the geometric mean of the OD490 was calculated from the triplicate wells. Generation of G and F Virus-Like Particles (VLPs) on RSV M and P or M and M2-1 Platforms

[0480] RSV VLPs were generated by sequentially transfecting 293F cells with codon-optimized DNA plasmids containing RSV genes. Western blot studies indicate successfully developed VLPs with RSV M plus P or M plus M2-1 protein platforms with F or F and G but only to very low levels with G alone, a condition not observed with F in VLPs expressing only F, i.e., detection of F or F and G in the supernatant and not the cell pellet of the induced 293F cells. VLPs are released from cells. Additionally, F or F and G were detected by Western blot in the pellet after centrifugation through a sucrose cushion indicating the proteins were incorporated into particles and not in solution in the media. Finally, F and M, or F, G, and M were detected by Western blot in the same fractions after sucrose gradient purification indicating presence of M in VLPs containing F and F and G.

[0481] Co-expressed F and G peptides with the intracellular, transmembrane, and first 20 amino acids of the extracellular domains (amino acids 1-86) plus amino acids 155-206 representing the central conserved domain (GP). VLPs with either the M plus P or M plus M2-1 platform were generated as indicated by Western blot studies of sucrose gradient purified VLPs. G alone was inefficiently but with F was efficiently incorporated into the VLPs suggested that F facilitated generation of G VLPs. A truncated F (Ft) with its carboxyl terminus plus transmembrane plus first 26 amino acids of the extracellular domain (Ft) was generated to co-express with full-length G. Ft, G is abundantly expressed in the VLPs (using the M plus P VLP).

[0482] Animal study

[0483] Four- to six-week old female BALB / c mice were immunized with 50 pg of VLPs on day 1 (prime) and on day 21 (boost) through intramuscular injection. The mice were euthanized on day 42 and serum was separated, stored at -80°C until use.

Claims

CLAIMS1. A recombinant RSV G protein comprising R15K, G29C, M48I, I49V, N81S, T87P, and R197K mutations.

2. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIV (SEQ ID NO: 27).

3. The recombinant RSV G protein of claim 1 comprising the amino acid sequence ofMSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNT (SEQ ID NO: 17, Ga 1-86).

4. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIAAIIFIASANHKVTPTTAIIQDATSQIKNTPP (SEQ ID NO: 18, Ga 1-86 C-terminal PP), MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIAAIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQ (SEQ ID NO: 34, Ga 1-96), orMSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTTPTYLTQNPQLGISPSNPSE (SEQ ID NO: 35, Ga 1- 106).

5. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of PSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQID NO: 19, Ga 155-206),QRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTCWAICKRIPNKKPGKKTTTKPTKKPTLK (SEQ ID NO: 36, Ga 150-210), orTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 37, Gb 150-210).

6. The recombinant RSV G protein of claim 1 comprising the amino acid sequence ofMSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIAS ANHKVTPTT AIIQD AT SQIKNTPP SKPNNDFHFEVFNF VPC SIC SNNPTC WAICKR IPNKKPGKKTTTKPTKKP (SEQ ID NO: 1, Ga 1-86 plus 155-206 (Ga)).

7. The recombinant RSV G protein of claim 1 comprising the amino acid sequence ofMSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAICKRIPNKKPGKKTTTKPTKKPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQL CKSICKTIPSNKPKKKPTIKPTNKPTTKT (SEQ ID NO: 5, group A 1-86 plus 150-210 plus group B 150-210, tandem Ga plus Gb (T-Ga / Gb)).

8. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of KPTLKTPRL (SEQ ID NO: 21, linker Gb).

9. The recombinant RSV G protein of claim 1 comprising the amino acid sequence ofQRQNKPP SKPNNDFHFEVFNF VPC SIC SNNPTCWAICKRIPNKKPGKKTTTKPTK KPTLKTPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKKKPTIKPTN KPTTKT (SEQ ID NO: 20, Gb 150-210).

10. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of MSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIAAIIFIAS ANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTC WAIACKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 9, Ga CX4C 1-86 plus 145-206).

11. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of KPTTKQRQNK (SEQ ID NO: 28, Ga 145-154).

12. The recombinant RSV G protein of claim 1 comprising the amino acid sequence of CWAIAC (SEQ ID NO: 22, Ga CX4C).

13. The recombinant RSV G protein of claim 1 comprising the amino acid sequence ofMSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICR NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 11, Ga 1-86 plus 145-206 S177R) orMSKNKDQRTAKTLERTWDTLNHLLFISSCLYKLNLKSVAQITLSILAIVISTSLIIA AIIFIASANHKVTPTTAIIQDATSQIKNTKPTTKQRQNKPPSKPNNDFHFEVFNFVPCSICQ NNPTCWAICKRIPNKKPGKKTTTKPTKKP (SEQ ID NO: 13, Ga 1-86 plus 145-206 S177Q).

14. The recombinant RSV G protein of claim 1 comprising a S177R and / or S177Q mutation.

15. A virus like particle comprising any of the recombinant RSV G protein as provided in claims 1-14.

16. A nucleic acid encoding the recombinant RSV G protein as provided in claims 1-14 in operable combination with a heterologous promoter.

17. The nucleic acid of claim 16 which is RNA or DNA.

18. A live attenuated RSV strain comprising an RSV G protein as provided in any of claims 1- 14.

19. A vector comprising a nucleic acid of claim 16 or encoding the recombinant RSV G protein as provided in claims 1-14.

20. A method of vaccinating against or treating for an RSV infection comprising administering an effective amount of a vaccine or pharmaceutical composition comprising RSV G protein, virus like particle, viral particle, nucleic acid, attenuated RSV stain, attenuated RSV virus, or vector as provided for in any of claims 1-19 to a subject in need thereof.

21. A vaccine or pharmaceutical composition comprising RSV G protein, virus like particle, viral particle, nucleic acid, attenuated RSV stain, attenuated RSV virus, or vector as provided for in any of claims 1-19 to a subject in need thereof.

Images